SANDRA GOFINET PASOTO
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
LIM/03 - Laboratório de Medicina Laboratorial, Hospital das Clínicas, Faculdade de Medicina
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
LIM/03 - Laboratório de Medicina Laboratorial, Hospital das Clínicas, Faculdade de Medicina
14 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 14
- V Brazilian consensus guidelines for detection of anti-cell autoantibodies on hep-2 cells (vol 59, 28, 2019)(2020) CRUVINEL, Wilson de Melo; ANDRADE, Luis Eduardo Coelho; MUHLEN, Carlos Alberto von; DELLAVANCE, Alessandra; XIMENES, Antonio Carlos; BICHARA, Carlos David; BUENO, Cleonice; MANGUEIRA, Cristovao Luis Pitangueira; BONFA, Eloisa; BRITO, Fabiano de Almeida; FLUMIAN, Fernanda Bull; SILVA, Glaucielen Gomes da; REGO, Jozelia; ANJOS, Lisiane Maria Ericoni dos; SLHESSARENKO, Natasha; PASOTO, Sandra Gofinet; NEVES, Suzane Pretti Figueiredo; VALIM, Valeria; SANTOS, Wilton Silva dos; FRANCESCANTONIO, Paulo Luiz CarvalhoAfter publication of the original article [1], we were notified that there is a mistake in Fig. 2.
- Anti-DNase I Antibody A New Serological Reactivity in Primary Sjogren Syndrome(2020) GRIFFO, Priscilla; VIANA, Vilma V. S. T.; PASOTO, Sandra G.; LEON, Elaine P.; BONFA, EloisaBackground and Objective: Primary Sjogren syndrome (pSS) is a systemic autoimmune rheumatic disease that particularly affects exocrine glands. Dry eye is one of the most important features of this syndrome, and a recent study reported reduced deoxyribonuclease I (DNase I) activity in the tear of patients with dry eye. We therefore postulated that patients with pSS might have antibodies targeting DNAse I. Methods: We have evaluated in a cross-sectional study 85 patients with pSS (2002 American-European Consensus Group Criteria), 50 rheumatoid arthritis (RA) patients (1987 American College of Rheumatology Criteria) without sicca symptoms, and 88 healthy volunteers. IgG anti-DNase I was detected by enzyme-linked immunosorbent assay using as antigen bovine pancreas enzyme and confirmed by immunoblotting. Results: Age and sex were alike in the 3 groups (p > 0.05). Anti-DNase I was detected in 43.5% of the pSS patients. In contrast, this reactivity was absent in all RA patients (p = 0.0001). Additional comparison of pSS patients with (n = 37) or without (n = 48) anti-DNase I showed that the former group had higher IgG serum levels (2293.2 +/- 666.2 vs 1483.9 +/- 384.6 mg/dL, p = 0.0001) and greater rate of non-drug-induced leukopenia (43% vs 19%, p = 0.02). A multivariate logistic regression analysis identified that only IgG levels were independently associated with anti-DNase I. Conclusions: We describe a high frequency of anti-DNase I antibodies in pSS patients associated with higher serum IgG levels. The lack of this reactivity in RA patients without sicca symptoms suggests that this antibody may be helpful in the differential diagnosis of these diseases.
- Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjogren's syndrome(2020) BRITO-ZERON, Pilar; ACAR-DENIZLI, Nihan; NG, Wan-Fai; HORVATH, Ildiko Fanny; RASMUSSEN, Astrid; SEROR, Raphaele; LI, Xiaomei; BALDINI, Chiara; GOTTENBERG, Jacques-Eric; DANDA, Debashish; QUARTUCCIO, Luca; PRIORI, Roberta; HERNANDEZ-MOLINA, Gabriela; ARMAGAN, Berkan; KRUIZE, Aike A.; KWOK, Seung-Ki; KVARNSTROM, Marika; PRAPROTNIK, Sonja; SENE, Damien; GERLI, Roberto; SOLANS, Roser; RISCHMUELLER, Maureen; MANDL, Thomas; SUZUKI, Yasunori; ISENBERG, David; VALIM, Valeria; WILAND, Piotr; NORDMARK, Gunnel; FRAILE, Guadalupe; BOOTSMA, Hendrika; NAKAMURA, Hideki; GIACOMELLI, Roberto; DEVAUCHELLE-PENSEC, Valerie; HOFAUER, Benedikt; BOMBARDIERI, Michele; TREVISANI, Virginia Fernandes Moca; HAMMENFORS, Daniel; PASOTO, Sandra G.; RETAMOZO, Soledad; GHEITA, Tamer A.; ATZENI, Fabiola; MOREL, Jacques; VOLLENWEIDER, Cristina; ZEHER, Margit; SIVILS, Kathy; XU, Bei; BOMBARDIERI, Stefano; SANDHYA, Pulukool; VITA, Salvatore De; MINNITI, Antonina; SANCHEZ-GUERRERO, Jorge; KILIC, Levent; HEIJDEN, Eefje van der; PARK, Sung-Hwan; WAHREN-HERLENIUS, Marie; MARIETTE, Xavier; RAMOS-CASALS, ManuelObjective. To characterize the systemic phenotype of primary Sjogren's syndrome at diagnosis by analysing the EULAR-SS disease activity index (ESSDAI) scores. Methods. The Sjogren Big Data Consortium is an international, multicentre registry based on worldwide data-sharing cooperative merging of pre-existing databases from leading centres in clinical research in Sjogren's syndrome from the five continents. Results. The cohort included 10 007 patients (9352 female, mean 53 years) with recorded ESSDAI scores available. At diagnosis, the mean total ESSDAI score was 6.1; 81.8% of patients had systemic activity (ESSDAI score >= 1). Males had a higher mean ESSDAI (8.1 vs 6.0, P < 0.001) compared with females, as did patients diagnosed at <35 years (6.7 vs 5.6 in patients diagnosed at >65 years, P < 0.001). The highest global ESSDAI score was reported in Black/African Americans, followed by White, Asian and Hispanic patients (6.7, 6.5, 5.4 and 4.8, respectively; P < 0.001). The frequency of involvement of each systemic organ also differed between ethnic groups, with Black/African American patients showing the highest frequencies in the lymphadenopathy, articular, peripheral nervous system, CNS and biological domains, White patients in the glandular, cutaneous and muscular domains, Asian patients in the pulmonary, renal and haematological domains and Hispanic patients in the constitutional domain. Systemic activity measured by the ESSDAI, clinical ESSDAI (clinESSDAI) and disease activity states was higher in patients from southern countries (P < 0.001). Conclusion. The systemic phenotype of primary Sjogren's syndrome is strongly influenced by personal determinants such as age, gender, ethnicity and place of residence, which are key geoepidemiological players in driving the expression of systemic disease at diagnosis.
- Clinical and laboratory features of African-Brazilian patients with systemic sclerosis(2020) MENDES, Cristiane; VIANA, Vilma S. T.; PASOTO, Sandra G.; LEON, Elaine P.; BONFA, Eloisa; SAMPAIO-BARROS, Percival D.Objective African-Brazilians comprise a group of blacks and ""pardos."" As racial differences can be associated with distinct presentations, we evaluated the clinical and serological associations of African-Brazilians with systemic sclerosis (SSc). Methods Sera from 260 adult SSc patients (203 whites and 57 African-Brazilians) were evaluated. Patients with overlap syndromes were excluded. Clinical and demographic data were obtained from an electronic register database. Laboratory analysis included the following: anti-CENP-A/CENP-B, Scl70, RNA polymerase III, Ku, fibrillarin, Th/To, PM-Scl75, and PM-Scl100 by line immunoassay and anti-nuclear antibodies (ANA) by indirect immunofluorescence (IIF) on HEp-2 cells. Results African-Brazilian SSc patients presented shorter disease duration (12.8 +/- 6.5 vs. 15.9 +/- 8.1 years, p = 0.009), higher frequency of nucleolar ANA pattern (28% vs. 13%, p = 0.008), and lower frequencies of centromeric ANA pattern (14% vs. 29%, p = 0.026) and CENP-B (18% vs. 34%, p = 0.017), as well as an association with severe interstitial lung disease (58% vs. 43%; p = 0.044). Further comparison of ethnic groups according to subsets revealed that diffuse SSc African-Brazilian patients presented higher frequency of pulmonary hypertension (p = 0.017), heart involvement (p = 0.037), nucleolar ANA pattern (p = 0.036), anti-fibrillarin antibodies (p = 0.037), and higher mortality (48% vs. 19%; p = 0.009). A different pattern was observed for the limited subset with solely a lower frequency of esophageal involvement (p = 0.050) and centromeric ANA pattern (p = 0.049). Survival analysis showed that African-Brazilians had a higher mortality, when adjusted for age, gender, and clinical subset (RR 2.06, CI 95% 1.10-3.83, p = 0.023). Conclusion African-Brazilians have distinct characteristics according to clinical subset and an overall more severe SSc than whites, similar to the blacks from other countries.
conferenceObject Hydroxychloroquine Blood Levels Predicts 6-Months Disease Activity in Juvenile Lupus Nephritis(2020) BALBI, Verena; SILVA, Clovis; PEDROSA, Tatiana; PEREIRA, Rosa; CAMPOS, Lucia; LEON, Elaine; DUARTE, Nilo; CARVALHO, Valdemir; PASOTO, Sandra; ROSARIO, Debora; BRANDAO, Leticia; BONFA, Eloisa; AIKAWA, Nadia- Lupus nephritis-related issues during COVID-19 pandemic quarantine(2020) PEDROSA, Tatiana; KUPA, Leonard de Vinci Kanda; AIKAWA, Nadia Emi; PASOTO, Sandra Gofinet; BONFA, Eloisa; SILVA, Clovis Artur
article 15 Citação(ões) na Scopus Autoimmune congenital heart block and primary Sjogren's syndrome: characterisation and outcomes of 49 cases(2020) BRITO-ZERON, P.; PASOTO, S. G.; ROBLES-MARHUENDA, A.; MANDL, T.; VISSINK, A.; ARMAGAN, B.; PRAPROTNIK, S.; NOCTURNE, G.; SEBASTIAN, A.; TREVISANI, V. Fernandes Moca; RETAMOZO, S.; ACAR-DENIZLI, N.; WILAND, P.; SISO-ALMIRALL, A.; BOOTSMA, H.; MARIETTE, X.; RAMOS-CASALS, M.; KOSTOV, B.Objective. To characterise autoimmune congenital heart block (CHB) associated with a maternal diagnosis of primary Sjogren's syndrome (pSS) confirmed either before, concomitant or after the first pregnancy complicated with CHB. Methods. The following inclusion criteria were applied: (i) Mothers with positive Ro/La autoantibodies detected previously or at the time of diagnosis of the first case of CHB; (ii) diagnosis of CHB confirmed by fetal echocardiography; (iii) AV block diagnosed in uterus, at birth or within the neonatal period (0-27 days after birth) (8); (iv) absence of anatomical cardiac abnormalities which might be causal of AV block; and (v) maternal fulfillment of the 2002 SS criteria before, during or after having a pregnancy complicated with CHB. Results. We identified 49 cases of autoimmune CHB in children born from 44 mothers who had a mean age at the time of pregnancy of 30.3 years (range 18 to 41). At the time of diagnosis of autoimmune CHB, all mothers had positive anti-Ro antibodies and 28/ 44 (64%) were positive for anti-La antibodies. Only 10 (22%) mothers with affected pregnancies had a diagnosis of primary SS at the time of diagnosis of the first pregnancy complicated by CHB (a mean of 4 years before, ranging from 1 to 10 years). In 6 (14%) mothers, primary SS was diagnosed during pregnancy or less than 12 months after the delivery/termination. In the remaining 28 ( 64%) mothers, pSS was confirmed 1-5 years after CHB diagnosis (n=19, 68%), 6-10 years after (n= 2, 7%), or more than 10 years after the first case of CHB was diagnosed (n=7, 25%). CHB was diagnosed in uterus in all cases but two. AV block was initially incomplete in 11 fetuses and complete in 36 (no available data in 2 cases). Among the 35 (71%) surviving children with CHB, 5 (14%) developed other features of neonatal lupus. After the index pregnancy, 12 women had 20 subsequent pregnancies: five were complicated by a CHB ( recurrence rate of CHB of 25%). The 4 women who had recurrent CHB were double-positive for anti-Ro and anti-La antibodies, and all had a confirmed pSS before having the first index case of CHB. Conclusion. In pSS, autoimmune CHB could be one of the first ""indirect"" signs of the disease in women of childbearing-age, in whom the diagnosis is confirmed several years later. Some maternal characteristics could be related with recurrent CHB, such as having an already-confirmed diagnosis of pSS and carrying the two Ro/La autoantibodies.- Juvenile Sjogren's Syndrome: Clinical Characteristics With Focus on Salivary Gland Ultrasonography(2020) HAMMENFORS, Daniel S.; VALIM, Valeria; BICA, Blanca E. R.; PASOTO, Sandra G.; LILLEBY, Vibke; NIETO-GONZALEZ, Juan Carlos; SILVA, Clovis A.; MOSSEL, Esther; PEREIRA, Rosa M. R.; COELHO, Aline; BOOTSMA, Hendrika; THATAYATIKOM, Akaluck; BRUN, Johan G.; V, Malin JonssonObjective Juvenile Sjogren's syndrome (SS) is a rare, poorly defined, and possibly underdiagnosed condition affecting children and adolescents. The aim of this study was to characterize symptoms and clinical findings of juvenile SS and to explore the clinical application of major salivary gland ultrasonography (SGUS) in patients with juvenile SS. Methods A cross-sectional multicenter study recruited patients with disease onset until age 18 years (n = 67). Disease characteristics were recorded, and unstimulated whole sialometry and SGUS examination of the parotid and submandibular salivary glands were performed. Results The female:male ratio was 58:9. The mean age at first symptom was 10.2 years and 12.1 years at diagnosis. Ocular and oral symptoms were noted in 42 of 67 patients (63%) and 53 of 66 patients (80%), respectively. The American-European Consensus Group or American College of Rheumatology/European League Against Rheumatism classification criteria for primary SS were fulfilled by 42 of 67 patients (63%). Pathologic SGUS findings were observed in 41 of 67 patients (61%); 26 of 41 SGUS+ patients (63%) fulfilled primary SS criteria. Salivary gland enlargements/parotitis were noted in 37 of 58 patients and were nonsignificantly associated with SGUS+ status (P = 0.066). The mean levels of saliva were 5.6 ml/15 minutes in SGUS- patients compared to 3.3 ml/15 minutes in the SGUS+ patients (P = 0.049). A total of 36 of 41 SGUS+ patients (88%) were anti-Ro/La+ compared to 14 of 26 SGUS- patients (54%) (P = 0.001). In addition, 24 of 39 SGUS+ patients (62%) were positive for rheumatoid factor (RF), whereas only 5 of 25 SGUS- patients (20%) were RF+ (P = 0.001). Conclusion Juvenile SS is characterized by a large spectrum of clinical symptoms and findings. Several glandular and extraglandular parameters such as hyposalivation, swollen salivary glands, and autoantibodies are associated with pathologic SGUS findings.
- Antibodies to cellular prion protein and its cognate ligand stress-inducible protein 1 in systemic lupus erythematosus(2020) CARVALHO, Jozelio F.; VIANA, Vilma S. T.; LEON, Elaine P.; BONFA, Eloisa; PASOTO, Sandra G.; MARTINS, Vilma R.Objectives This study aimed to determine the prevalence of autoantibodies to cellular prion protein (PrP(C)) and its cognate ligand stress-inducible protein 1 (STI-1) in sera from patients with systemic lupus erythematosus (SLE), and their possible correlation with clinical and serological SLE manifestations. Methods Sera were obtained from 103 consecutive SLE patients and 77 healthy controls. IgG antibodies to PrP(C) and to STI-1 were determined by ELISA using recombinant purified proteins, and the reactivities were confirmed by immunoblotting. A panel of lupus-related autoantibodies was investigated by well-standardized techniques. Clinical data were obtained by extensive chart review, and disease activity was scored using the SLE Disease Activity Index (SLEDAI). Results The frequency of anti-PrP(C) antibodies in SLE (7.8%) was similar to healthy controls (p = 0.56), but these antibodies were significantly associated with previous central nervous system (CNS) involvement when compared with patients without anti-PrP(C) (33.3% vs. 7.5%;p = 0.04). On the other hand, anti-STI-1 reactivity was more frequently observed in SLE patients than in healthy controls (12.6% vs. 2.6%;p = 0.026), and this reactivity was associated with a lower frequency of renal disease (23.1% vs. 54.4%;p = 0.04). These two antibody specificities were not associated with SLEDAI score or with the presence of lupus autoantibodies (p > 0.05). Conclusion This is the first evidence of reactivity to PrP(C) in SLE. The intriguing association of these antibodies and previous CNS involvement raises the possibility of a pathogenic role for them in SLE CNS damage.
- RETRACTION: Antibodies to cellular prion protein and its cognate ligand stress-inducible protein 1 in systemic lupus erythematosus (Retraction of Vol 93, Pg 861, 2020)(2020) CARVALHO, J. F.; VIANA, V. S. T.; LEON, E. P.; BONFA, E.; PASOTO, S. G.; MARTINS, V. R.